Prostate Cancer Medical Services in China

Prostate cancer is a malignant neoplasm arising from the glandular epithelium of the prostate, predominantly affecting men over age 50. Risk factors include advancing age, family history, African ancestry, and certain genetic mutations (e.g., BRCA2). Clinical presentation may range from asymptomatic elevated serum prostate-specific antigen (PSA) to lower urinary tract symptoms, hematuria, or skeletal pain in advanced disease. Diagnosis relies on digital rectal examination, PSA testing, multiparametric MRI, and transrectal ultrasound-guided biopsy with histopathological confirmation. Staging incorporates TNM classification, Gleason score (now integrated into Grade Groups), and risk stratification (low-, intermediate-, or high-risk) to guide management. Treatment modalities include active surveillance for low-risk disease; radical prostatectomy (open, laparoscopic, or robotic-assisted); external beam radiotherapy (including intensity-modulated radiotherapy and stereotactic body radiotherapy); brachytherapy; and systemic therapies—such as androgen deprivation therapy, next-generation anti-androgens (e.g., enzalutamide), and radioligand therapy (e.g., ¹⁷⁷Lu-PSMA)—for advanced or metastatic cases.

China offers compelling advantages for international patients seeking prostate cancer care. The country hosts nationally accredited cancer centers with urologic oncology specialists trained at leading institutions worldwide and actively engaged in multinational clinical trials. State-of-the-art infrastructure includes da Vinci Xi surgical systems, MRI-linear accelerator hybrids, and PSMA PET/CT imaging—widely deployed across tier-1 hospitals in Beijing, Shanghai, and Guangzhou. Five-year biochemical recurrence-free survival after robotic prostatectomy exceeds 90% for localized disease, consistent with global benchmarks. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical standards—making high-value care accessible. As a dedicated medical tourism agency, we facilitate seamless access: verifying hospital credentials, coordinating multidisciplinary consultations, securing priority appointments, managing visa support and accommodation, and providing transparent, all-inclusive pricing—ensuring continuity of care from initial inquiry through post-treatment follow-up.

China offers a compelling option for prostate cancer treatment, combining advanced care with significant cost savings—typically 40–60% lower than in the U.S. or Western Europe for equivalent procedures such as robotic-assisted laparoscopic prostatectomy or intensity-modulated radiation therapy. Leading hospitals in Beijing, Shanghai, and Guangzhou utilize state-of-the-art equipment, including da Vinci Xi surgical systems and MRI-guided radiotherapy platforms, supported by urologic oncologists with extensive experience managing complex cases. Many centers participate in international clinical collaborations and adhere to NCCN-informed protocols, ensuring evidence-based care. Through our agency, patients receive transparent, itemized pricing upfront, personalized hospital matching based on clinical needs and language support preferences, and dedicated budget planning—including estimates for treatment, accommodation, and follow-up. The treatment process is streamlined: initial remote consultation, visa assistance, airport-to-hospital transfers, and coordinated appointments—all managed centrally. Post-treatment follow-up can be arranged remotely or during a planned return visit. This integrated approach reduces logistical burden while maintaining clinical rigor and financial predictability.

The international patient treatment process for prostate cancer begins with a remote consultation: patients submit medical records (diagnostic imaging, pathology reports, PSA levels, prior treatment summaries) for review by our partner uro-oncology specialists. Our agency schedules the initial virtual or in-person consultation within 3–5 business days, coordinating time zones and language preferences. We provide certified medical translation of all documents and real-time interpretation during consultations and follow-up appointments. Once a treatment plan is confirmed—whether active surveillance, surgery (robotic/laparoscopic), radiation therapy, or systemic therapy—our team arranges hospital admission, secures appointment slots with minimal wait time (typically 7–14 days post-approval), and coordinates airport transfers and verified accommodation near the hospital. Throughout treatment, a dedicated care coordinator accompanies patients to appointments, assists with medication logistics, and facilitates communication between clinicians and the patient/family. Required materials include passport, medical history summary, recent lab/imaging reports, and referral letter (if applicable). The full process—from initial inquiry to treatment completion—generally takes 3–6 weeks, depending on diagnostic needs and treatment modality. All services include 24/7 multilingual support (English, Mandarin, Arabic, Spanish) and assistance with visa documentation and insurance coordination.

Medical Travel to China Guide: Prostate Cancer (Urology)

Visa & Entry: Most nationalities require a Chinese Medical Visa (Q2 or S2), obtainable with our clinic invitation letter and medical referral. We assist with document preparation and embassy coordination.

Medical Insurance & Payment: International health insurance is rarely accepted in China; we provide transparent, all-inclusive pricing upfront—covering diagnostics, surgery (e.g., robotic-assisted prostatectomy), anesthesia, hospital stay, and nursing. You pay directly to the hospital pre-treatment via secure bank transfer or credit card (with 3% fee); we verify costs line-by-line and help negotiate if needed.

Accommodation & Companions: We arrange verified, hospital-near apartments or hotels (single/double rooms) with Wi-Fi, kitchen access, and daily cleaning. One companion may accompany you at no extra cost for medical appointments; additional guests receive discounted rates.

Follow-Up Care: Post-discharge, our clinical coordinators schedule virtual oncology consultations every 2–4 weeks for 6 months, share pathology reports securely, and coordinate local lab tests or imaging back home. We also translate discharge summaries and treatment records into English and support referrals to your home urologist.